DE60316709D1 - Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren - Google Patents

Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren

Info

Publication number
DE60316709D1
DE60316709D1 DE60316709T DE60316709T DE60316709D1 DE 60316709 D1 DE60316709 D1 DE 60316709D1 DE 60316709 T DE60316709 T DE 60316709T DE 60316709 T DE60316709 T DE 60316709T DE 60316709 D1 DE60316709 D1 DE 60316709D1
Authority
DE
Germany
Prior art keywords
gluccokinase
carbonateaureamides
activators
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60316709T
Other languages
English (en)
Other versions
DE60316709T2 (de
Inventor
Wendy Lea Corbett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60316709D1 publication Critical patent/DE60316709D1/de
Publication of DE60316709T2 publication Critical patent/DE60316709T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60316709T 2002-10-03 2003-09-26 Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren Expired - Lifetime DE60316709T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41573702P 2002-10-03 2002-10-03
US415737P 2002-10-03
PCT/EP2003/010776 WO2004031179A1 (en) 2002-10-03 2003-09-26 Indole-3-carboxamides as glucokinase (gk) activators

Publications (2)

Publication Number Publication Date
DE60316709D1 true DE60316709D1 (de) 2007-11-15
DE60316709T2 DE60316709T2 (de) 2008-07-17

Family

ID=32069904

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316709T Expired - Lifetime DE60316709T2 (de) 2002-10-03 2003-09-26 Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren

Country Status (29)

Country Link
US (1) US6881844B2 (de)
EP (1) EP1549638B1 (de)
JP (1) JP4390704B2 (de)
KR (1) KR100646486B1 (de)
CN (1) CN100348596C (de)
AR (1) AR041467A1 (de)
AT (1) ATE374768T1 (de)
AU (1) AU2003270285B2 (de)
BR (1) BR0315047A (de)
CA (1) CA2499329C (de)
DE (1) DE60316709T2 (de)
DK (1) DK1549638T3 (de)
ES (1) ES2293005T3 (de)
HK (1) HK1083098A1 (de)
HR (1) HRP20050287A2 (de)
MX (1) MXPA05003391A (de)
MY (1) MY136764A (de)
NO (1) NO20051103L (de)
NZ (1) NZ538466A (de)
PA (1) PA8584001A1 (de)
PE (1) PE20050090A1 (de)
PL (1) PL375149A1 (de)
PT (1) PT1549638E (de)
RU (1) RU2309956C2 (de)
SI (1) SI1549638T1 (de)
TW (1) TW200413364A (de)
UY (1) UY28005A1 (de)
WO (1) WO2004031179A1 (de)
ZA (1) ZA200502619B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CA2498089A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1532980A1 (de) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-Heteroaryl Indol-Carboxamide und deren analoga zur Vewendung als glucokinase Aktivatoren zur Behandlung von Diabetes
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
WO2006112549A1 (ja) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited 縮合複素環化合物
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
CA2623958C (en) * 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
JP2009013065A (ja) * 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
EP2001875A2 (de) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase-aktivatoren
EP1849785A1 (de) * 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-Amid-Derivative als GSK-3 Inhibitoren
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
MX2009003972A (es) 2006-10-19 2009-04-27 Takeda Pharmaceutical Compuesto de indol.
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EA020332B1 (ru) * 2007-08-10 2014-10-30 Х. Лундбекк А/С Аналоги гетероариламидов
UY31830A (es) 2008-05-16 2010-01-05 Takeda Pharmaceutical Activadores de glucoquinasa
WO2010107736A2 (en) * 2009-03-20 2010-09-23 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
JP2011006366A (ja) 2009-06-26 2011-01-13 Sanwa Kagaku Kenkyusho Co Ltd 新規チオフェンカルボキサミド誘導体及びその医薬用途
EP2632460B1 (de) 2010-09-20 2018-02-28 University of Virginia Patent Foundation Thiophen-derivate zur verwendung in der behandlung von tuberkulose
CN103044310B (zh) * 2013-01-18 2015-02-04 贵阳医学院 二氢吲哚-3-乙酸衍生物、其制备方法以及在药物中的应用
EP4419503A1 (de) * 2021-10-20 2024-08-28 Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) Verfahren zur herstellung von indol-3-carbonsäure-derivaten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP5278983B2 (ja) 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
AU2190202A (en) 2000-12-06 2002-06-18 Hoffmann La Roche Fused heteroaromatic glucokinase activators
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
TWI312779B (de) 2000-12-28 2009-08-01 Daiichi Seiyaku Co
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use

Also Published As

Publication number Publication date
KR20050046817A (ko) 2005-05-18
DE60316709T2 (de) 2008-07-17
SI1549638T1 (sl) 2008-02-29
CN100348596C (zh) 2007-11-14
KR100646486B1 (ko) 2006-11-15
DK1549638T3 (da) 2008-01-21
JP4390704B2 (ja) 2009-12-24
CA2499329A1 (en) 2004-04-15
HRP20050287A2 (en) 2006-12-31
US20040067939A1 (en) 2004-04-08
PL375149A1 (en) 2005-11-28
TW200413364A (en) 2004-08-01
PT1549638E (pt) 2007-12-11
BR0315047A (pt) 2005-08-23
AU2003270285A1 (en) 2004-04-23
NO20051103L (no) 2005-04-08
AR041467A1 (es) 2005-05-18
ZA200502619B (en) 2006-03-29
JP2006504707A (ja) 2006-02-09
EP1549638A1 (de) 2005-07-06
US6881844B2 (en) 2005-04-19
UY28005A1 (es) 2004-04-30
RU2309956C2 (ru) 2007-11-10
PA8584001A1 (es) 2004-11-02
CN1688574A (zh) 2005-10-26
HK1083098A1 (en) 2006-06-23
MY136764A (en) 2008-11-28
EP1549638B1 (de) 2007-10-03
RU2005113719A (ru) 2006-02-27
MXPA05003391A (es) 2005-06-22
AU2003270285B2 (en) 2007-04-26
NZ538466A (en) 2007-05-31
ATE374768T1 (de) 2007-10-15
ES2293005T3 (es) 2008-03-16
WO2004031179A1 (en) 2004-04-15
CA2499329C (en) 2009-04-21
PE20050090A1 (es) 2005-02-28

Similar Documents

Publication Publication Date Title
DE60316709D1 (de) Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
DK1572670T3 (da) 5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer
ATE297921T1 (de) Tetrazolylphenyl-acetamide als glukokinaseaktivatoren
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
NO20043116L (no) Amidderivater som GK-aktivatorer
DE60336538D1 (de) Stabilisiervorrichtung
DE60305903D1 (de) Tropanderivative als ccr5-modulatoren
NO20044046L (no) Substituerte hydroksyetylaminer
DE60312863D1 (de) Fahrgestell
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
DE60236403D1 (de) Tourbillonmechanismus
NO20023047D0 (no) Kompenseringsanordning
ITMI20020198A0 (it) (per)aloeteri
DE60217480D1 (de) 17-METHYLEN-ANDROSTAN-3a-OL-ANALOGA ALS CRH- INHIBITOREN
DE50310329D1 (de) Steuergerat
DE60315020D1 (de) (2s)-2-ethylphenylpropionsäurederivat
DE60309612D1 (de) Steuergerät
DE50205540D1 (de) Steuergerät
FI20021277A0 (fi) Tuloilmalaite
DE60327250D1 (de) Modifizierte bace
ATE350379T1 (de) Substituierte benzdioxepine
SE0203213D0 (sv) Resevåg
ITLE20020026A1 (it) Compensatore di ossigeno

Legal Events

Date Code Title Description
8364 No opposition during term of opposition